Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 16.99% is 16% above its 5-year average of 14.60%, near the high end of its 5-year range (10.04%–17.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.44% below its 12-month average of 17.06%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): 4.28%.
RETURN ON ASSETS (ROA)
16.99%
RETURN ON ASSETS (ROA) AVG TTM
17.06%
RETURN ON ASSETS (ROA) AVG 3Y
15.57%
RETURN ON ASSETS (ROA) AVG 5Y
14.60%
RETURN ON ASSETS (ROA) AVG 10Y
12.91%
RETURN ON ASSETS (ROA) AVG 15Y
13.10%
RETURN ON ASSETS (ROA) AVG 20Y
12.04%
CURRENT VS TTM AVG
-0.44%
CURRENT VS 3Y AVG
+9.12%
CURRENT VS 5Y AVG
+16.34%
CURRENT VS 10Y AVG
+31.61%
CURRENT VS 15Y AVG
+29.71%
CURRENT VS 20Y AVG
+41.09%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+230.54%
vs the sector median at left
ResMed Inc.
Market Cap
$32.19B
Return on Assets (ROA)
16.99%
TTM Avg
17.06%
3Y Avg
15.57%
5Y Avg
14.60%
Market Cap
$33.01B
Return on Assets (ROA)
15.49%
TTM Avg
11.04%
3Y Avg
9.26%
5Y Avg
8.83%
Market Cap
$33.40B
Return on Assets (ROA)
14.54%
TTM Avg
-0.12%
3Y Avg
-10.91%
5Y Avg
-15.37%
Market Cap
$30.70B
Return on Assets (ROA)
24.67%
TTM Avg
25.02%
3Y Avg
24.63%
5Y Avg
23.85%
Market Cap
$30.58B
Return on Assets (ROA)
-6.14%
TTM Avg
-2.29%
3Y Avg
0.04%
5Y Avg
0.75%
Market Cap
$29.98B
Return on Assets (ROA)
4.27%
TTM Avg
5.83%
3Y Avg
5.87%
5Y Avg
14.86%
Market Cap
$29.48B
Return on Assets (ROA)
17.35%
TTM Avg
17.37%
3Y Avg
16.33%
5Y Avg
15.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $32.19B | 16.99% | 17.06% | 15.57% | 14.60% |
| Alcon Inc. (ALC)vs › | $31.49B | 2.06% | 3.23% | 2.72% | 1.72% |
| DexCom, Inc. (DXCM)vs › | $33.01B | 15.49% | 11.04% | 9.26% | 8.83% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $33.40B | 14.54% | -0.12% | -10.91% | -15.37% |
| Biogen Inc. (BIIB)vs › | $33.45B | 2.60% | 5.11% | 6.74% | 8.29% |
| Mettler-Toledo International Inc. (MTD)vs › | $30.70B | 24.67% | 25.02% | 24.63% | 23.85% |
| Centene Corp. (CNC)vs › | $30.58B | -6.14% | -2.29% | 0.04% | 0.75% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.98B | 4.27% | 5.83% | 5.87% | 14.86% |
| Zoetis Inc. (ZTS)vs › | $29.48B | 17.35% | 17.37% | 16.33% | 15.33% |
| Medline Inc. (MDLN)vs › | $29.31B | 1.76% | 3.17% | 1.75% | 1.75% |
ROA
17.0%
ROE
23.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | 16.99% |
| 2025-06-30 | 17.14% |
| 2024-06-30 | 14.86% |
| 2023-06-30 | 13.29% |
| 2022-06-30 | 15.30% |
| 2021-06-30 | 10.04% |
| 2020-06-30 | 13.55% |
| 2019-06-30 | 9.85% |
| 2018-06-30 | 10.30% |
| 2017-06-30 | 9.87% |
| 2016-06-30 | 10.81% |
| 2015-06-30 | 16.17% |
| 2014-06-30 | 14.62% |
| 2013-06-30 | 13.89% |
| 2012-06-30 | 11.92% |
| 2011-06-30 | 10.97% |
| 2010-06-30 | 11.69% |
| 2009-06-30 | 9.71% |
| 2008-06-30 | 7.85% |
| 2007-06-30 | 5.30% |
| 2006-06-30 | 8.76% |
| 2005-06-30 | 8.37% |
| 2004-06-30 | 10.43% |
| 2003-06-30 | 9.95% |
| 2002-06-30 | 9.97% |
| 2001-06-30 | 4.04% |
| 2000-06-30 | 19.23% |
| 1999-06-30 | 17.91% |
| 1998-06-30 | 16.41% |
| 1997-06-30 | 13.66% |
